Semaglutide vs. tirzepatide: does switching GLP-1s actually work?

What did @henspireroost actually say?

Here's the awkward part: the transcript attached to this video is song lyrics, not health commentary. The caption, however, does make real medical claims worth examining. The creator says semaglutide didn't work for them personally, that "all bodies are different," and that their body "needed that extra GIP receptor boost you get with tirzepatide." Those are the claims on the table.

To be fair, the caption is relatively measured. It doesn't promise tirzepatide will work for everyone, and it frames the experience as personal. But the GIP mechanism explanation is presented with enough confidence that viewers may take it as established medical reasoning for why they too should switch drugs. That framing deserves a closer look.

Does the science back this up?

Partially, yes. Tirzepatide is genuinely a dual agonist, meaning it activates both GLP-1 and GIP receptors, while semaglutide targets only GLP-1 receptors. That part is accurate pharmacology. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found tirzepatide produced up to 22.5% mean body weight reduction in people with obesity, outcomes that exceeded what comparable semaglutide trials reported.

However, claiming that the GIP receptor is the reason a specific individual had better results is a significant leap. Researchers still debate exactly what role GIP agonism plays. Some animal studies suggest GIP receptor activation in the brain contributes to reduced food intake, but the precise human mechanism remains under investigation. Attributing one person's differential response to GIP specifically is speculative, not settled science.

What did they get wrong (or right)?

The creator gets credit for framing this as a personal experience rather than a universal prescription. "All bodies are different" is not just a platitude here. Pharmacogenomic variability in GLP-1 receptor expression is real, and individual response differences across this drug class are documented in clinical literature.

Where the caption oversimplifies is in the mechanistic explanation. Saying your body "needed that extra GIP receptor boost" implies a level of self-diagnosis that no patient can reliably make without biomarker data. Non-response to semaglutide could reflect dosing, adherence, dietary factors, gut microbiome composition, or receptor polymorphisms. Pinning it specifically on GIP receptor insufficiency makes a tidy story out of genuinely complex biology.

The hashtag "semiglutide" is a misspelling of semaglutide, which is a minor point but worth noting in a health content context where drug names matter.

What should you actually know?

Switching between GLP-1 class medications is a real clinical option, and it does happen. A prescribing clinician may recommend transitioning from semaglutide to tirzepatide when weight loss plateaus or when side effects are limiting. But that decision should be driven by a structured clinical assessment, not a TikTok caption.

The SURMOUNT and STEP trial programs show tirzepatide and semaglutide are both effective, with tirzepatide showing larger average weight loss in head-to-head comparisons. However, average trial outcomes don't predict individual results. Some patients respond strongly to semaglutide and see modest results with tirzepatide. There is no validated test to predict which drug will work better for a given person before trying it.

If you feel like your current GLP-1 isn't working, that's a conversation for your prescriber, not a conclusion to draw from someone else's experience on a 19-thousand-view TikTok.

The bottom line

The creator's personal experience is valid. The mechanistic explanation they offer is a reasonable lay interpretation of real pharmacology, but it's oversimplified in ways that could mislead viewers into thinking they understand why a drug switch might work for them. Switching GLP-1 therapies is a legitimate clinical pathway. The reasoning behind any switch should come from a licensed provider who knows your full medical picture.

• Tirzepatide's dual-agonist mechanism is real and well-documented.
• Individual non-response to semaglutide has multiple possible explanations, not just GIP receptor dynamics.
• Head-to-head data does favor tirzepatide for average weight loss, but individual results vary substantially.
• Drug switching decisions require clinical oversight, not self-diagnosis from mechanism summaries.